The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease
Current care standards recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) regardless of glycemic compensation in patients with type 2 diabetes (T2DM) and kidney disease, heart failure, or high cardiovascular (CV) risk. A recent study published in the Clinical Journal of the American Society of Nephrology (CJASN) assessed whether long-term use of SGLT2i brings benefits compared to dipeptidyl peptidase-4 inhibitors (DPP4i, i.e., gliptins) in diabetics without documented CV or renal disease using data from a large Israeli database.
Study Methodology
Patients with type 2 diabetes who initiated treatment with gliflozins (empagliflozin or dapagliflozin) or DPP4i (sitagliptin, linagliptin, vildagliptin, saxagliptin) available in Israel between 2015 and 2021 were matched based on propensity score (1:1) using 90 parameters. The renal composite parameter included a confirmed reduction of at least 40% in estimated glomerular filtration rate (eGFR) or kidney failure. The "kidney-or-death" indicator additionally included all-cause mortality. The decline in eGFR was also compared. The authors analyzed the overall population and a subgroup of diabetics without documented cardiovascular and renal disease at study entry.
A total of 19,648 patients were included, of which 53% (10,467) had low cardiorenal risk. The median follow-up period was 38 months.
Findings
The renal composite parameter occurred with a frequency of 6.9 vs. 9.5 events per 1,000 patient-years for SGLT2i vs. DPP4i, and the kidney-or-death parameter at 17.7 vs. 22.1 events per 1,000 patient-years. The initiation of SGLT2i was associated with a significant reduction in the risk of the renal composite parameter (hazard ratio [HR] 0.72; 95% CI 0.61–0.86; p < 0.001) and the kidney-or-death parameter (HR 0.80; 95% CI 0.71–0.89; p < 0.001) compared to DPP4i. In patients without cardiovascular or renal disease, the initiation of SGLT2i compared to DPP4i led to a lower risk of the kidney-or-death parameter (HR 0.77; 95% CI 0.61–0.97), while the risk reduction of the renal composite parameter showed only a statistically insignificant trend (HR 0.67; 95% CI 0.44–1.02).
SGLT2i treatment also slowed the eGFR decline compared to DPP4i in both the overall diabetic population (by 0.49 ml/min/1.73 m2/year) and in diabetics without cardiovascular or renal disease (by 0.48 ml/min/1.73 m2/year).
Conclusion
In a study involving nearly 20,000 patients with T2DM, long-term use of SGLT2i compared to DPP4i in real-world practice was associated with a slower decline in eGFR and a reduced risk of the composite parameter, which includes significant deterioration of renal function (≥ 40% decline in eGFR/kidney failure) or all-cause mortality, in both the overall population and in diabetics without cardiovascular or renal disease at study entry.
(esr)
Source: Melzer-Cohen C., Schechter M., Rozenberg A. et al. Long-term, real-world, kidney function changes with SGLT2i versus DPP4i type 2 diabetes without cardiovascular or kidney disease. CJASN 2023 Sep 1; 18 (9): 1153−1162, doi: 10.2215/CJN.0000000000000218.
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
